Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Bulldog Investors Cuts Firsthand Technology Value Fund

Bulldog Investors/Firsthand Technology Value Fund: Philip Goldstein and Andrew Dakos’ Bulldog Investors recently trimmed its position in Firsthand Technology Value Fund (NASDAQ:SVVC), reducing the amount of owned shares to 632,668, from 726,356 held earlier. In this way, Bulldog Investors now holds 7.39% of the company, which is down by around 1.1 percentage points from the position held at the end of last month. At the current price of Firsthand Technology’s stock, the total value of shares owned by Bulldog amounts to $15.9 million.

Firsthand Technology Value Fund

This is not the first bearish move made by Bulldog Investors in Firsthand Technology Value Fund. At the end of last month, Goldstein and Dakos’ fund also sold some shares of the company, reducing the position from 833,900 shares.

Wilmot B. Harkey and Daniel Mack‘s Nantahala Capital Management, and Stanley Shopkorn and Douglas Day‘s Hilltop Park Associates also reported owning stakes in Firsthand Technology Value Fund, holding around 121,000 shares and 44,000 shares respectively.

Disclosure: none

Recommended Reading:

Baker Street Capital Closes Entire Unilens Stake in Buyback

BlueMountain Increases Activist Stake in Eastman Kodak to 20% of Company

How to Play Merger Arbitrage Cliff Asness Style

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!